Halia Therapeutics, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Active:1
Completed:3
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)โข Click on a phase to view related trials
Phase 1
2 (50.0%)Not Applicable
1 (25.0%)Phase 2
1 (25.0%)HT-6184 in Subjects With MDS
Not Applicable
Active, not recruiting
- Conditions
- Myelodysplastic SyndromeAnemia in Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Halia Therapeutics, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT07052006
- Locations
- ๐ฎ๐ณ
Nil Ratan Sircar Medical College and Hospital, Kolkata, Bengal, India
๐ฎ๐ณHemato Oncology Clinica Ahmedabad Pvt. Ltd. Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India
๐ฎ๐ณShalby Hospital, Ahmedabad, Gujarat, India
Study to Evaluate HT-4253 in Healthy Subjects
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Halia Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06537817
- Locations
- ๐ฆ๐บ
CMAX Clinical Research, Adelaide, South Australia, Australia
Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Halia Therapeutics, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT06241742
- Locations
- ๐บ๐ธ
CenExel JBR, Murray, Utah, United States
Study to Evaluate HT-6184 in Healthy Subjects
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Halia Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05447546
- Locations
- ๐บ๐ธ
TKL Research, Inc., Fair Lawn, New Jersey, United States
News
No news found